Breakpoint is developing innovative cancer therapies with support from eminent experts across the fields of oncology and DNA damage response research.
We collaborate with KOLs whose foundational work paved the way for the development and approval of the first DDR-targeted drugs as well as scientists at the cutting edge of cancer biology. Our network spans a spectrum of advisors from academic leaders in basic research to renowned drug hunters and clinical specialists attuned to patient needs and regulatory requirements.
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
